Small Business Resources, Business Advice and Forms from AllBusiness.com
Finance Resource Center   D&B Credit Reports   Businesses for Sale   What's Your Credit Emergency?   Thriving in Tough Times   Trade Magazines
 

Featured Videos

FDA issues warning letter over mailer

By McGuire, Stephen
Publication: Medical Marketing and Media
Date: Thursday, November 1 2007

THE FDA HAS issued Eli Lilly a warning letter over effectiveness

claims the company made in a 2005 promotional mailer to physicians for its blockbuster antidepressant/nerve pain treatment Cymbalta.

In a letter posted to the FDA's Web site, the agency said Lilly's promotion intended to promote its indication as a treatment for diabetic nerve pain was "false and misleading" and omitted some of the most serious and important risk information associated with its use.

The agency asked that Lilly stop using the material or any similar promos. A spokesman told The Indianapolis Star that the company is working with the FDA "to gain a greater understanding of their concerns." The spokesman said Lilly will take action once it has "more clarity" on the agency's comments.

IMAGE ILLUSTRATION1

The FDA asserts a 2005 mailer omitted serious risk info

Launched in 2004, Cymbalta has become Lilly's fastest-growing drug, with global sales of $1.3 billion in 2006. -SM

In addition, make sure to read these articles:

  • Lilly prepares for Cymbalta launch
    • MAKERS OF antidepressants braced themselves as Eli Lilly won approval for Cymbalta (duloxetine), which will be positioned as the first drug to treat the physical ......
  • Antidepressant market grows
    • There is an estimated 21 million Americans affected by depression and this year antidepressant revenues are expected to grow 13.7 percent and exceed $10 billion, ......
  • Staying power pays off
    • HEADNOTE Marketing Team of the Year, Large Pharma Wellbutrin XL IMAGE PHOTOGRAPH 1 Rob Jagt (left) and Steven O'Quinn In a crowded antidepressant market, one ......
  • Lexapro gains ease fears of generics
    • LOSS OF PATENT protection on Pfizer's Zoloft last year caused analysts to raise warning flags about the whole class. But the surprisingly strong performance of ......
  • FDA to Lilly: Can Cymbalta journal ads
    • THE FDA called on Eli Lilly to stop journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail ......
T T T
art_print_gray Print art_email Email 16x16-digg-guy  Digg It delicious-small  del.icio.us

Related Resources

icon - press release

Press Releases

Premium Content

presented by

Site Map | Contact Us | FAQs | About Us | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy

Media Kit
Copyright © 1999 - 2009 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.

© Copyright Haymarket Media, Inc. Nov 2007
Provided by ProQuest, LLC. All rights Reserved.

You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report?
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists | Company Profiles
Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.